Skip to main content

Table 1 Baseline clinical characteristics

From: A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus

 

Ezetimibe (n  = 17)

Atorvastatin (n  = 16)

p-value

Age (years)

64.2 ± 9.8

65.0 ± 8.0

0.81

Sex, male (%)

7 (41.2%)

8 (50.0%)

0.73

Body mass index (kg/m2)

22.5 ± 2.4

23.3 ± 3.5

0.45

Hypertension (%)

9 (56.3%)

9 (52.9%)

1.00

Current smoking (%)

4 (23.5%)

4 (25.0%)

1.00

Hemoglobin A1c (%)

7.3 ± 1.1

6.9 ± 0.6

0.18

Fasting plasma glucose (mg/dL)

135.8 ± 21.5

131.4 ± 21.4

0.57

Duration of diabetes (yeas)

13.6 ± 8.1

11.9 ± 9.3

0.58

Total cholesterol (mg/dL)

237.5 ± 25.8

226.6 ± 29.5

0.27

LDL cholesterol (ng/mL)

148.8 ± 22.1

135.6 ± 19.7

0.08

HDL cholesterol (mg/dL)

57.0 ± 11.3

54.9 ± 19.0

0.71

Triglyceride (mg/dL)

112.0 (100.0–192.5)

134.5 (76.3–229.3)

0.83

Anti-diabetic medicines

-

-

-

 Sulfonylureas (%)

2 (11.8%)

5 (31.5%)

0.23

 Metformin (%)

5 (29.4%)

4 (25.0%)

1.00

 Alpha-glucosidase inhibitor (%)

5 (29.4%)

6 (37.5%)

0.72

 Thiazolidinedione (%)

1 (5.9%)

2 (12.5%)

0.60

 Glinide (%)

0 (0%)

1 (6.3%)

0.49

 DPP-4 inhibitor (%)

1 (5.9%)

2 (12.5%)

0.60

 Insulin (%)

8 (47.1%)

3 (18.8%)

0.14

Any anti-diabetic medications (%)

14 (82.3%)

14 (87.5%)

0.53

LnRHI

0.471 ± 0.157

0.552 ± 0.084

0.076

  1. LDL: low-density lipoprotein, HDL: high-density lipoprotein, DPP-4: dipeptidyl peptidase-4, LnRHI: natural logarithmic transformed value of reactive hyperemia peripheral tonometry index.